Changing the molecular profile of primary and metastatic breast cancer identified by Foundation One: case report

Autores

DOI:

https://doi.org/10.29289/2594539420210053

Palavras-chave:

breast neoplasms, metastasis, biopsy, cytogenetic analysis

Resumo

Objective: To describe a case report of a patient who presented with bilateral breast cancer with progression to metastatic
disease, in which immunohistochemical profile of the primary and metastatic tumor was divergent. Methods: This was a study
with a descriptive narrative and reflective design, of the case report type, based on secondary data, with information and images
obtained from the electronic medical records of the MVSoul system used in the oncology center of a private hospital in the Federal
District in Brazil. Data collection was derived from the analysis of data and images of the electronic medical record. Case report:
A patient presented with bilateral metastatic breast cancer, and the primary and metastatic breast tumors showed a difference in
immunohistochemical profile. Accordingly, we highlight the rarity of the case, the need for biopsies of metastatic lesions because
of the molecular heterogeneity of breast cancer and possible discrepancy between the primary tumor and metastases. Spreading
knowledge about diagnostic tests and personalized treatment according to tumor molecular characteristics is also essential,
especially when the patient does not have a satisfactory therapeutic response, as in the reported case, since the patient had
metastases with different molecular profiles confirmed only by of tumor DNA sequencing.

Downloads

Não há dados estatísticos.

Referências

Brazil. Ministério da Saúde. Instituto Nacional de Câncer José Alencar Gomes da Silva. Estatísticas de Câncer [internet]. Rio de Janeiro: Inca; 2021. [cited on October 10, 2021]. Available at: https://www.inca.gov.br/numeros-de-cancer

Franzoi MA, Rosa DD, Zaffaroni F, Werutsky G, Simon S, Bines J, et al. Advanced stage at diagnosis and worse clinicopathologic features in young women with breast cancer in Brazil: a subanalysis of the AMAZONA III study (GBECAM 0115). J Glob Oncol. 2019;5:1-10. https://doi.org/10.1200/JGO.19.00263

Spronk I, Schellevis FG, Burgers JS, Bock GH, Korevaar JC. Incidence of isolated local breast cancer recurrence and contralateral breast cancer: a systematic review. Breast. 2018;39:70-9. https://doi.org/10.1016/j.breast.2018.03.011

Langballe R, Frederiksen K, Jensen MB, Andersson M, Cronin-Fenton D, Ejlertsen B, et al. Mortality after contralateral breast cancer in Denmark. Breast Cancer Res Treat. 2018;171(2):489-99. https://doi.org/10.1007/s10549-018-4846-3

Rasmussen CB, Kjær SK, Ejlertsen B, Andersson M, Jensen MB, Christensen J, et al. Incidence of metachronous contralateral breast cancer in Denmark 1978-2009. Int J Epidemiol. 2014;43(6):1855-64. https://doi.org/10.1093/ije/dyu202

Provenzano E, Ulaner GA, Chin SF. Molecular classification of breast cancer. PET Clin. 2018;13(3):325-38. https://doi.org/10.1016/j.cpet.2018.02.004

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736-50. https://doi.org/10.1093/jnci/djp082

Bitencourt AGV, Lima ENP, Chojniak R, Marques EF, Souza JA, Luciana Graziano L, et al. Correlação entre resultado do PET/CT e achados histológicos e imuno-histoquímicos em carcinomas mamários. Radiol Bras. 2014;47(2):67-73. https://doi.org/10.1590/S0100-39842014000200006

Caldarella A, Buzzoni C, Crocetti E, Bianchi S, Vezzosi V, Apicella P, et al. Invasive breast cancer: a significant correlation between histological types and molecular subgroups. J Cancer Res Clin Oncol. 2013;139(4):617-23. https://doi.org/10.1007/s00432-012-1365-1

Corben AD. Pathology of invasive breast disease. Surg Clin North Am. 2013;93(2):363-92. https://doi.org/10.1016/j.suc.2013.01.003

Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30(21):2601-8. https://doi.org/10.1200/JCO.2011.37.2482

Lee Y, Kang E, Lee AS, Baek H, Kim EK, Park SY, et al. Outcomes and recurrence patterns according to breast cancer subtypes in Korean women. Breast Cancer Res Treat. 2015;151(1):183-90. https://doi.org/10.1007/s10549-015-3390-7

Shim HJ, Kim SH, Kang BJ, Choi BG, Kim HS, Cha ES, et al. Breast cancer recurrence according to molecular subtype. Asian Pac J Cancer Prev. 2014;15(14):5539-44. https://doi.org/10.7314/apjcp.2014.15.14.5539

van Uden DJP, van Maaren MC, Strobbe LJA, Bult P, van der Hoeven JJ, Siesling S, et al. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer. Breast Cancer Res. 2019;21(1):113. https://doi.org/10.1186/s13058-019-1201-5

Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271-7. https://doi.org/10.1200/JCO.2009.25.9820

Kolberg-Liedtke C, Wuerstlein R, Gluz O, Heitz F, Freudenberger M, Bensmann E, et al. Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet. Breast Care (Basel). 2021;16(5):475-83. https://doi.org/10.1159/000512416

Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023-31. https://doi.org/10.1038/nbt.2696

Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011;3(111):111ra121. https://doi.org/10.1126/scitranslmed.3003161

National Comprehensive Cancer Network. NCCN Guidelines. Fort Washington: National Comprehensive Cancer Network; 2021 [cited on October 10, 2021]. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419.

Downloads

Publicado

2026-04-17

Como Citar

Montechi, I. F. V., Schorn, P. W., Cabral, A. D., Santos, J. S., & Silva, A. V. L. e. (2026). Changing the molecular profile of primary and metastatic breast cancer identified by Foundation One: case report. Mastology, 32. https://doi.org/10.29289/2594539420210053

Edição

Seção

Case Reports